Description: Kainos Medicine, Inc. researches and develops various medicines for cancers, and brain and infectious diseases in South Korea and internationally. The company's product pipeline includes KM-819, which is completed Phase I clinical study for the treatment of Parkinson's disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is in Phase III clinical study to treat HIV/AIDS. It is also developing anticancer agents, including DNA methyltransferase inhibitor; gene target anti-cancer agent; and Ara-C, a cytotoxic anti-cancer agent to treat acute myeloid leukemia, as well as small molecule immuno-oncology drugs that modulate anti-cancer abilities of immune cells. In addition, the company is involved in the discovery of a Hepatitis B drug. It has a collaboration agreement with Emmaus Life Sciences, Inc. for the preclinical development of IRAK4 inhibitor as potential anti-cancer drug. Kainos Medicine, Inc. was founded in 2007 and is headquartered in Seongnam, South Korea.
Home Page: www.kainosmedicine.com
Institute Pasteur Korea
Seongnam-si,
13488
South Korea
Phone:
82 2 567 7419
Officers
| Name | Title |
|---|---|
| Mr. Ki-Sub Lee | Chairperson, Co-Founder & CEO |
| Dr. Jaemoon Lee Ph.D. | Chief Bus. Officer, VP of Biology & Internal Director |
| Dr. In Chull Kim | Chief Strategic Officer |
Exchange: KQ
Country: KR
Currency: Korean Won (₩)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |